Sera Prognostics (NASDAQ:SERA) Stock Rating Upgraded by Wall Street Zen

Key Points

• Sera Prognostics has received an upgrade from Wall Street Zen, moving from a "sell" to a "hold" rating, though its consensus rating remains a "sell" according to MarketBeat.com.
• The company reported a quarterly loss of ($0.16) per share, surpassing analyst expectations of ($0.21), but its revenue was below estimates at only $0.02 million.
• Insiders, including CEO Zhenya Lindgardt, have sold shares of the company recently, which may indicate lowered confidence amid a backdrop of mixed institutional investor activity.

Sera Prognostics (NASDAQ:SERA - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Sera Prognostics in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Sell".

Sera Prognostics Price Performance

Shares of NASDAQ SERA opened at $3.65 on Friday. The company has a market cap of $137.50 million, a PE ratio of -4.29 and a beta of 0.97. Sera Prognostics has a 12 month low of $1.37 and a 12 month high of $9.13. The company has a 50-day simple moving average of $3.09 and a 200-day simple moving average of $2.71.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. On average, analysts anticipate that Sera Prognostics will post -0.96 EPS for the current year.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 21,158 shares of the business's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total transaction of $66,647.70. Following the completion of the sale, the chief executive officer directly owned 811,136 shares in the company, valued at $2,555,078.40. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 50,631 shares of company stock worth $153,604 in the last ninety days. 13.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Sera Prognostics

Several institutional investors have recently bought and sold shares of SERA. Aberdeen Group plc purchased a new stake in Sera Prognostics during the first quarter worth approximately $4,563,000. AWM Investment Company Inc. grew its stake in Sera Prognostics by 48.1% during the first quarter. AWM Investment Company Inc. now owns 866,837 shares of the company's stock worth $3,190,000 after buying an additional 281,703 shares during the period. Sanders Morris Harris LLC grew its stake in Sera Prognostics by 179.8% during the second quarter. Sanders Morris Harris LLC now owns 263,600 shares of the company's stock worth $730,000 after buying an additional 169,400 shares during the period. Perkins Capital Management Inc. purchased a new stake in Sera Prognostics during the first quarter worth approximately $522,000. Finally, Captrust Financial Advisors grew its stake in Sera Prognostics by 20.0% during the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company's stock worth $1,668,000 after buying an additional 100,366 shares during the period. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.